Clinical Study

Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vegfr-Targeted Therapy

Posted Date: May 17, 2019

  • Investigator: David Steward
  • Specialties: Oncology, Otolaryngology, Thyroid Cancer
  • Type of Study: Drug

The purpose of this study is to evaluate the effect of cabozantinib compared with a placebo in treating patients whose disease has progressed after receiving prior treatment with drugs that inhibit growth of tumor blood vessel (VEGFR-targeted therapy) for their thyroid cancer.




Thyroid Cancer, Cabozantinib

For More Information:


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.